Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Equity to Asset 0.26
BIOS's Equity to Asset is ranked higher than
55% of the 332 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. BIOS: 0.26 )
BIOS' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.66
Current: 0.26

0.26
0.66
F-Score: 2
Z-Score: 0.62
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -9.27
BIOS's Operating margin (%) is ranked lower than
51% of the 348 Companies
in the Global Medical Care industry.

( Industry Median: 9.21 vs. BIOS: -9.27 )
BIOS' s 10-Year Operating margin (%) Range
Min: -11.69   Max: 4.61
Current: -9.27

-11.69
4.61
Net-margin (%) -14.98
BIOS's Net-margin (%) is ranked lower than
52% of the 348 Companies
in the Global Medical Care industry.

( Industry Median: 4.59 vs. BIOS: -14.98 )
BIOS' s 10-Year Net-margin (%) Range
Min: -16.05   Max: 9.77
Current: -14.98

-16.05
9.77
ROE (%) -49.24
BIOS's ROE (%) is ranked lower than
54% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 10.46 vs. BIOS: -49.24 )
BIOS' s 10-Year ROE (%) Range
Min: -57.57   Max: 43.05
Current: -49.24

-57.57
43.05
ROA (%) -16.74
BIOS's ROA (%) is ranked lower than
53% of the 353 Companies
in the Global Medical Care industry.

( Industry Median: 4.18 vs. BIOS: -16.74 )
BIOS' s 10-Year ROA (%) Range
Min: -27.23   Max: 20.26
Current: -16.74

-27.23
20.26
ROC (Joel Greenblatt) (%) -68.95
BIOS's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 350 Companies
in the Global Medical Care industry.

( Industry Median: 17.58 vs. BIOS: -68.95 )
BIOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.86   Max: 227.09
Current: -68.95

-902.86
227.09
Revenue Growth (3Y)(%) 12.20
BIOS's Revenue Growth (3Y)(%) is ranked higher than
86% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. BIOS: 12.20 )
BIOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -35   Max: 15.9
Current: 12.2

-35
15.9
EPS Growth (3Y)(%) 493.40
BIOS's EPS Growth (3Y)(%) is ranked higher than
99% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. BIOS: 493.40 )
BIOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.7   Max: 493.4
Current: 493.4

-82.7
493.4
» BIOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIOS Guru Trades in Q2 2014

Mario Gabelli 1,440,840 sh (+75.98%)
Mario Gabelli 2,255,552 sh (+175.48%)
Steven Cohen 416,500 sh (unchged)
Ron Baron 144,010 sh (unchged)
Pioneer Investments 280,320 sh (unchged)
» More
Q3 2014

BIOS Guru Trades in Q3 2014

Ron Baron 281,300 sh (+95.33%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 1,431,426 sh (-0.65%)
Steven Cohen 92,100 sh (-77.89%)
» More
Q4 2014

BIOS Guru Trades in Q4 2014

Ron Baron 345,500 sh (+22.82%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 1,178,601 sh (-17.66%)
» More
2015

BIOS Guru Trades in 2015

Mario Gabelli 7,666,300 sh (+14.97%)
Mario Gabelli 6,668,300 sh (+17.81%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on BioScrip Inc

Baron Funds Comments on BioScrip Inc. - Feb 26, 2014

BioScrip, Inc. (BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about BioScrip Inc

Two Gurus Hold Stakes in Embattled BioScrip
BioScrip Inc (BIOS), a New York-based national provider of infusion and home care management solutions, announced last month the sale of $62.5 million in Series A Convertible Preferred Stock to Coliseum Capital Management, LLC, and related funds. Read more...
A Look at Mario Gabelli's Latest Stake Increases
Mario Gabelli (Trades, Portfolio) has continued to use the same formula for success since 1976 when he founded GAMCO Investors. The firm has continued to use a bottom-up research strategy with a consistent investment process. Read more...
Mario Gabelli Boosts BioScrip Inc. Position
Mario Gabelli (Trades, Portfolio), the founder of the $49.4 billion asset management firm GAMCO Investors (GBL), has increased his stake in BioScrip Inc. (BIOS), according to GuruFocus Real Time Picks. Gabelli holds 3,636,600 shares, or 5.3% of the company, after the 40.2% position increase. Read more...
Gurus' Real Time Stock Picks of the Week
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The “Real Time Picks” reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases and buys in Real Time activity from Mario Gabelli (Trades, Portfolio) and Robert Karr (Trades, Portfolio). Read more...

Ratios

vs
industry
vs
history
Forward P/E 32.89
BIOS's Forward P/E is ranked higher than
63% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. BIOS: 32.89 )
N/A
P/B 1.60
BIOS's P/B is ranked higher than
87% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. BIOS: 1.60 )
BIOS' s 10-Year P/B Range
Min: 0.3   Max: 3.1
Current: 1.6

0.3
3.1
P/S 0.37
BIOS's P/S is ranked higher than
92% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 1.90 vs. BIOS: 0.37 )
BIOS' s 10-Year P/S Range
Min: 0.04   Max: 1.89
Current: 0.37

0.04
1.89
EV-to-EBIT -7.87
BIOS's EV-to-EBIT is ranked higher than
58% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 30.37 vs. BIOS: -7.87 )
BIOS' s 10-Year EV-to-EBIT Range
Min: -509.1   Max: 1645.4
Current: -7.87

-509.1
1645.4
Current Ratio 1.16
BIOS's Current Ratio is ranked higher than
67% of the 335 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. BIOS: 1.16 )
BIOS' s 10-Year Current Ratio Range
Min: 0.86   Max: 2.17
Current: 1.16

0.86
2.17
Quick Ratio 0.93
BIOS's Quick Ratio is ranked higher than
62% of the 335 Companies
in the Global Medical Care industry.

( Industry Median: 1.12 vs. BIOS: 0.93 )
BIOS' s 10-Year Quick Ratio Range
Min: 0.82   Max: 1.86
Current: 0.93

0.82
1.86
Days Inventory 17.62
BIOS's Days Inventory is ranked higher than
81% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 42.57 vs. BIOS: 17.62 )
BIOS' s 10-Year Days Inventory Range
Min: 0.52   Max: 80.5
Current: 17.62

0.52
80.5
Days Sales Outstanding 52.21
BIOS's Days Sales Outstanding is ranked higher than
71% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 54.36 vs. BIOS: 52.21 )
BIOS' s 10-Year Days Sales Outstanding Range
Min: 23.97   Max: 164.17
Current: 52.21

23.97
164.17

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 29.20
BIOS's Price/DCF (Projected) is ranked higher than
71% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. BIOS: 29.20 )
BIOS' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 38.83
Current: 29.2

0.72
38.83
Price/Median PS Value 1.50
BIOS's Price/Median PS Value is ranked higher than
62% of the 407 Companies
in the Global Medical Care industry.

( Industry Median: 1.40 vs. BIOS: 1.50 )
BIOS' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 3.65
Current: 1.5

0.21
3.65
Earnings Yield (Greenblatt) -12.70
BIOS's Earnings Yield (Greenblatt) is ranked lower than
60% of the 338 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. BIOS: -12.70 )
BIOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.7   Max: 9.5
Current: -12.7

-12.7
9.5
Forward Rate of Return (Yacktman) -88.38
BIOS's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 11.24 vs. BIOS: -88.38 )
BIOS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -88.6   Max: 51.5
Current: -88.38

-88.6
51.5

Business Description

Industry: Health Care Providers » Medical Care
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:MM6.Germany,
BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The Company operates in three reportable segments: Infusion Services, Home Health Services, and Pharmacy Benefit Management Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment products and services. Infusion Services include the dispensing and administering of infusion-based drugs, which requires additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home Health Services provides services that include the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home. The integrated Pharmacy Benefit Management Services' operating and reportable segment consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. The discount card allows an individual to receive prescription medications at a discounted price compared to the retail price. The Company has approximately 250 sales and marketing representatives and over 1,000 payor relationships including MCOs, Medicare Part D pharmacy networks, other government programs such as Medicare and Medicaid and other Third Party Payors. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusio
» More Articles for BIOS

Headlines

Articles On GuruFocus.com
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 
A Look at Mario Gabelli's Latest Stake Increases Apr 01 2015 
Mario Gabelli Ups Stake in BioScript, But Value of Stock Declines Mar 18 2015 
A Look at Mario Gabelli's New Added Positions Feb 04 2015 
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 
Morning Coffee: Real-Time Guru Picks Apr 02 2014 
Baron Funds Comments on BioScrip Inc. Feb 26 2014 

More From Our Partners
Zacks Rank #5 Additions for Tuesday - Tale of the Tape Apr 14 2015 - ZACKS

More From Other Websites
Zacks Rank #5 Additions for Tuesday - Tale of the Tape Apr 14 2015
BioScrip (BIOS) in Focus: Stock Adds 5.2% in Session - Tale of the Tape Apr 10 2015
BioScrip (BIOS) Stock Is Up Today on New Analyst Rating Apr 09 2015
4 Stocks Under $10 Making Big Moves Apr 07 2015
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of BioScrip, Inc. Stockholders Apr 06 2015
Lifshitz & Miller Law Firm Announces Investigation of Auspex Pharmaceuticals, Inc., BioScrip, Inc.,... Apr 03 2015
The Shuman Law Firm Investigates BioScrip, Inc. Apr 01 2015
CBRE Group Inc (CBG) Spikes to Record High; Check Out the Top Picks of One of Its Investors Cloud... Apr 01 2015
Zacks Rank #5 Additions for Wednesday - Tale of the Tape Apr 01 2015
3 Stocks Under $10 to Trade for Big Breakouts Mar 31 2015
Zacks Rank #5 Additions for Wednesday - Tale of the Tape Mar 25 2015
BIOSCRIP, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Regulation FD... Mar 24 2015
BioScrip Inc (BIOS): Coliseum Capital’s New Activist Target Mar 20 2015
Zacks Rank #5 Additions for Wednesday - Tale of the Tape Mar 18 2015
IPOs & Transactions Week in Review: March 9 - 13 /plus VDR video demonstration Mar 16 2015
BioScrip, Inc. -- Moody's: BioScrip's convertible preferred stock issuance is credit positive;... Mar 13 2015
BioScrip (BIOS) in Focus: Stock Moves 11.8% Higher - Tale of the Tape Mar 13 2015
Zacks Rank #5 Additions for Thursday - Tale of the Tape Mar 12 2015
Why BioScrip (BIOS) Could Be Positioned for a Slump - Tale of the Tape Mar 11 2015
BIOSCRIP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK